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Crohn’s disease aﬀects increasing numbers of children worldwide. Generally, childhood-onset disease runs a more severe course
than in adults and has a greater impact on quality of life. Therapy in children must take account of a diﬀerent set of risks for
toxicity compared to adults, but also to their longevity. Biologic drugs present remarkable advantages in terms of disease control
for children, especially in those whose disease cannot be controlled with conventional therapies, but their long-term risks are
still being assessed. Data regarding biologic use in children is limited and mostly amounts to case series, but results have been
promising, both in terms of controlling disease activity and improving growth parameters. Adverse reactions are infrequent in the
short term, but loss of response is a long-term problem, particularly in children. More information is needed about very long term
risks. Inﬂiximab and adalimumab are the most studied agents in children, while there is relatively limited data on certolizumab
and natalizumab. Further collection of data on these agents is still needed, but this should not restrict access to these agents for
children in whom no other agent is eﬀective.
1.Introduction
The last 20 years have seen an evolution in the approach
to therapy of Crohn’s disease in both children and adults.
The further development of ASA-based drugs, introduction
of immunomodulators, and adoption of a “top-down” ap-
proach to early disease have brought substantial therapeutic
beneﬁt. However, persisting treatment failures lead to the
development of a new class of drugs—biologicals—which
have been used to target speciﬁc cytokines and receptors
thoughttobepivotalintheperpetuationofintestinalinﬂam-
mation. Although a number have been developed, only a few
have proven eﬃcacy and entered standard clinical practice.
A substantial proportion of patients develop Crohn’s disease
in childhood, but there are few studies of eﬃcacy or safety
of these new biologicals in this vulnerable population. The
purpose of this paper is to summarise the information
available on the eﬃcacy and risks of available biologicals in
childhood Crohn’s disease.
2.Background
The incidence of childhood Crohn’s disease appears to
be increasing globally [1, 2]. The cause of this increase
remains elusive, but it is now recognised to be occurring
in both developed and developing nations [1] and in
adults [3]. Crohn’s disease, particularly in youth, results in
signiﬁcant morbidity, impairment in quality of life [4], and
consumption of health care resources [5]. Children and their
families especially feel its impact on their productivity [6].
Gender ratios diﬀer from adults, with a male to female ratio
of 1.5 to 1.0 in children less than 15 years of age compared to
an equal gender ratio in adults with Crohn’s [7].
Childhood-onset Crohn’s disease tends to be character-
ized by ileocolonic or colonic involvement at outset [8, 9]
rather than isolated ileal disease, as is seen more often in
adults. Isolated colonic involvement is particularly apparent
in early-onset paediatric disease [9, 10], as is isolated oral
or perianal disease [9]. Diﬀuse involvement of multiple seg-
ments is common in children compared to the 1-2 localized2 Gastroenterology Research and Practice
segments more frequently seen in adults [8, 9, 11–13]. Upper
gastrointestinalinvolvementisalsomorefrequentinchildren
at diagnosis than in adults. Disease extension tends to be
more common in the ﬁrst decade after diagnosis in children,
although time to ﬁrst surgery is delayed compared to adults
[9, 13]. Children generally present with purely inﬂammatory
disease, as opposed to the often penetrating or stricturing
presentations seen in adults [8, 9]. Disease progression is
also altered, with children developing complicated disease at
a greater rate, despite increasing use of immunomodulators
[8]. After 5 years of disease, the incidence of complicated
disease is similar for children and adults [9]. This is an
especially devastating observation, which is compounded by
the simple fact that children spend more of their life at risk
of these complications.
The genetics of paediatric CD has speciﬁc diﬀerences,
mirroring its phenotypic distinctions. While there are many
susceptibility loci common to adults and children, ﬁve new
loci associated with childhood-onset disease have recently
been identiﬁed through genome-wide association studies
[14]. A full understanding of genes at these loci may be years
away, and it remains unclear what impact these discoveries
will have on clinical practice (if any) [15].
A growing pharmacopoeia of biologic drugs has broad-
ened the treatment arsenal in the last ﬁfteen years. In chil-
dren, the two phases of treatment are induction and main-
tenance of remission. In the past, medical treatment options
were limited. Induction mainstays have been corticosteroids
and enteral nutrition [16]. Maintenance therapies include
thiopurines, methotrexate, antibiotics, aminosalicylates, and
enteral therapy [17–19]. There is some evidence that, while
the acute responses to steroids is similar for adults (80–
84%) and children (84–89%), a prolonged response may
be more likely to be achieved in children (50–61% versus
32–44%) [20]. This may be related to a greater proportion
of children who receive early immunomodulators. Despite
this, there is still a signiﬁcant proportion of children who
fail these therapies altogether, experience signiﬁcant toxicity,
or become dependent upon corticosteroids [21]. In these
children with otherwise refractory disease, biological agents
have opened new horizons and become a mainstay of
therapy, with important implications for improved growth
and bone health. Indeed, there is evidence that the utility
of a biological may be greater in children than in adults. At
least one clinic which treats both adults and adolescents with
inﬂammatory bowel disease has reported using biologicals in
a substantially greater proportion of adolescents (20%) than
adults (8%) [22].
Biologic drugs leverage components of the human
immune system to target molecules implicated in the
pathogenesis of Crohn’s [23]. Most target the proinﬂam-
matory cytokine tumour necrosis factor alpha (TNFα).
Inﬂiximab (Remicade) was the ﬁrst drug of this class,
synthesisedasamouse-humanchimera[24].Afullyhuman-
ised molecule, adalimumab (Humira), and certolizumab
(Cimzia), a polyethylene-glycolated antibody-binding frag-
ment, have since followed. Natalizumab (Tysabri), an α-
integrin monoclonal antibody, has also been used in the
management of paediatric CD.
Most trial evidence for the use of biologics comes
from adults, and while there is more similarity than diﬀer-
ence between adults and children, this literature must be
interpreted with caution [25, 26]. Given the more severe
phenotype, duration, and genetic diﬀerences of paediatric-
onset CD, it may be that an entirely diﬀerent therapeutic
approach is warranted. Eﬃcacy studies examining the early
use of immunomodulators such as thiopurines in children
[27] have formed the basis of what is now known as
“top-down” therapy [28]. This term was coined to deﬁne
“aggressive initial therapy” with “disease modifying agents”
[28], and is currently considered to encompass early use
of either or both biologicals and immunomodulators [20].
There is some evidence which points to the possible eﬃcacy
of “top-down” therapy with biologicals, where children
identiﬁed as likely to have progressive disease are aggressively
treated with early immunomodulators and/or biologics [29].
The diﬃculty lies in identifying those whose disease is likely
to run a more aggressive course, for whom potential beneﬁts
should outweigh risks.
Disease activity indices used in children are diﬀerent
from those used in adults, adding a further layer of
complexity. Since Crohn’s disease can have a substantial
impact on growth, the Paediatric Crohn’s Disease Activity
Index (PCDAI) includes height and weight criteria [30]. It
is weighted more towards objective laboratory values when
compared with the adult Crohn’s Disease Activity Index
(CDAI) [31]. The PCDAI has been shown to be a responsive,
well-validated index with good reliability [32]. It can be
used to establish baseline severity and to deﬁne treatment
outcomes such as partial treatment response or complete
remission. Deﬁnitions of secondary loss of response to
treatment vary, but this is generally considered to have
occurred if a child does not remain in remission, as deﬁned
by the PCDAI. The importance of mucosal healing in the
long-term prognosis of disease is well acknowledged and
should also be considered as an outcome measure [33].
3.ClinicalEfﬁcacy
There is a paucity of authoritative evidence regarding the use
of biologics in paediatric CD. Inﬂiximab is the main agent
used, with other biologics used mostly in the event of lost
responsetoinﬂiximabtherapy.Therearenotrialscomparing
the relative eﬃcacy of one biologic with another. Paediatric
evidenceregardingtheuseofbiologicsinthemanagementof
ﬁstulising and postsurgical patients is scant.
3.1. Inﬂiximab. Randomised controlled trial evidence
regarding the use of inﬂiximab is conﬁned to adults. Here,
inﬂiximab has proven eﬃcacy for induction, maintenance,
and for the treatment of ﬁstulae [34–36]. For induction in
children, eﬃcacy is inferred from Level 3 and 4 evidence
[37]. In these studies, the rate of successful induction
is approximately 88%. In early paediatric pilot studies,
induction of remission was seen ﬁrst with a single dose, then
in a multiple-dose induction regimen of doses at zero, two,
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[40] showed higher rates of successful induction than in
many adults. For example, in a somewhat comparable group
receiving both azathioprine and inﬂiximab, the rate of
steroid-free remission was only 47% after induction [41].
For maintenance, the REACH study also provides the
best support for the use of inﬂiximab in children [40]. In this
multicentre, open-label study, 112 children (median age: 13
years) were all given three doses of inﬂiximab for induction.
At ten weeks, all were assessed for treatment response. Those
who responded were then randomised to receive further
maintenance treatment with inﬂiximab, either every eight
weeks or every twelve weeks. Participants were followed for
a total of ﬁfty-four weeks. Response and remission were
deﬁned with appropriate PCDAI values.
At ten weeks, 88.4% had responded and 58.9% entered
remission. At ﬁfty-four weeks, in those receiving inﬂiximab
every eight or twelve weeks, respectively, 55.8% and 23.5%
remained in remission. These data suggest that inﬂiximab
does have some eﬃcacy in children. However, the REACH
study has signiﬁcant limitations, including the lack of a
control group during induction, the universal use of concur-
rent immunomodulators, the unblinded nature of the study,
randomization of participants to a dose frequency which
was almost certain to be inferior, and, extensive involvement
of the manufacturer in the design, data acquisition, and
authorship of the study. These limitations obfuscate the
true size of the treatment eﬀect. They also add further
diﬃculty when making comparisons with adult data. The
onlytherapeuticpropertyofinﬂiximabthatthisstudyproves
beyond contention is that it should be given every eight
weeks for maintenance in children.
The possibility of using inﬂiximab only in episodes
of exacerbated disease was raised due to concerns about
minimising exposure to biologics in children. The study by
Ruemmele and colleagues conﬁrms that scheduled doses are
superior to episodic therapy in children, at least in terms of
treatment eﬀect [42]. Forty children were given open-label
inﬂiximab induction. Those who entered remission (n =
34) were then randomised to regular inﬂiximab every eight
weeks or to receive inﬂiximab only should they develop an
exacerbation. After sixty weeks of total followup, those who
had received scheduled maintenance were more likely to be
in remission (83% versus 63%; P = 0.011); however, the
study’s methodology limits the signiﬁcance of these results.
Of most concern, the study used the Harvey-Bradshaw Index
(HBI), which is based on, but correlates poorly with, the
CDAI [43, 44]. Neither the CDAI nor the HBI has been
validated foruse in children. Inany case,most clinicians now
use inﬂiximab on a scheduled basis in maintenance.
Secondary loss of response to inﬂiximab is a major
limiting factor in maintenance therapy. It may require dose
escalation or the cessation of inﬂiximab therapy. Within the
ﬁrst year, in adults with luminal disease, approximately 30%
will lose response [35]. In children with luminal disease, a
similar number also lose response (36.5% in the REACH
study) [40]. Beyond the length of followup possible with
RCTs, cohort studies provide important information about
thelong-termdurabilityofinﬂiximabtherapy.Thereappears
to be no upper limit to the proportion of patients who
will experience secondary loss of response. In one cohort of
children receiving maintenance inﬂiximab, only 33% were
still in remission (not requiring corticosteroids or surgery)
by three years [45].
Thereappearstobesomecorrelationbetweentheratesof
secondary loss of response and the acquisition of antibodies
to inﬂiximab, in both adults and children [35, 46, 47]. The
rate of secondary loss of response may be reduced with
scheduled maintenance therapy and the use of concurrent
immunomodulators such as methotrexate or thiopurines;
however, these should be used with caution in children, due
to concerns about the possible risks for malignancy (see the
section “Adverse Eﬀects,” below) [46, 48, 49].
Theearlyandaggressiveuseofinﬂiximabinselectedpae-
diatric patients is a nascent area of research. The top-down
approach to therapy supposes that early disease (commonly
possessing inﬂammatory behaviour) is the most amenable to
early aggressive therapy such as with immunosuppressants
or biologicals, given that inﬂiximab, for instance, targets
the inﬂammatory cascade [29]. Indeed, children with early
disease display immunological features that disappear later
in the course of disease [50]. By intervening early, it may be
possible to prevent progression to stenosing or penetrating
disease (so-called disease modiﬁcation).
In children, Kim and colleagues address the issue of top-
down therapy with inﬂiximab in a case series [51]. The
study took eleven patients resistant to conventional therapy
(step-up group) and eighteen treatment na¨ ıve patients with
moderate to severe disease (top-down group). All were given
inﬂiximab induction and maintenance therapy for one year.
More patients in the top down group were in remission after
induction,andaftertenmonthsofmaintenancetherapy.The
limitations of this study are clear, but the possible superior
eﬃcacy of top-down therapy in children cannot be excluded
at this stage.
The key issues in top down therapy, which remain
unresolved, are to reliably indentify those patients who will
go on to experience complications, so warranting the risks
of aggressive therapy [29], as well as those who will receive
therapeutic beneﬁt from biologicals [52].
3.2. Adalimumab. Again, randomised controlled trial
evidence for the eﬃcacy of adalimumab is conﬁned to
adults. Here it has been proven eﬀective in both the
induction and maintenance of remission [53–55]. These
studies include patients who are both na¨ ıve to biologics
and those who have failed inﬂiximab therapy. Adalimumab
has also been shown to reduce hospital admissions and
CD-related surgery [56]. As with other biologics, there
appears to be a considerable rate of secondary loss of
response, with one case series describing a 21% cumulative
probability by one year [57]. We await the published results
of a large, double-blind, paediatric study listed as complete
on http://www.clinicaltrials.gov/ct2/show/NCT00409682?
term=NCT00409682—this study and results are available in
abstract form.
In children, limited prospective evidence comes from
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was conducted in relatively older patients (median age: 16
years) with moderate to severe CD. Twenty-three patients
received adequate loading doses at zero and two weeks and
then went on to receive forty-eight weeks of maintenance.
61% were in remission after induction, and 65% were in
remission by the end of the study. Immunomodulators and
corticosteroids were used as clinically indicated during the
study, and requirements were signiﬁcantly lower at the end
of the study.
There is retrospective evidence that supports the use
of adalimumab in children. The RESEAT cohort reports
outcomes in 115 children (mean age at diagnosis: 11 years)
who had almost all previously received inﬂiximab [59]. Loss
of response or adverse reaction to inﬂiximab had occurred in
92% of subjects. By one year, the rate of clinical remission
was 42%, demonstrating some eﬃcacy of adalimumab as
a rescue therapy for children who fail inﬂiximab. A survey
of UK and Ireland clinicians describes seventy-two patients
and reports a higher rate of remission (61%), but diﬀering
baseline patient characteristics and study methodologies
make it very diﬃcult to compare these two studies [60]. A
smaller Israeli cohort (n = 14) also demonstrated eﬃcacy in
children with severe treatment refractory CD [61].
3.3. Certolizumab. Certolizumab shows evidence of moder-
ate eﬃcacy in adults with CD [62–64]. There are currently
no published studies in children regarding the eﬃcacy of this
drug, but two trials are currently in progress (NCT00899678,
NCT01190410).
3.4. Natalizumab. Natalizumab was ﬁrst developed for use
in multiple sclerosis. The ENCORE trial demonstrated
moderate eﬃcacy in the induction of remission in adult
Crohn’s [65]. Hyams and colleagues conducted a small
case-series with the primary aim of assessing the safety of
natalizumab in adolescents with Crohn’s [66]. In secondary
analysis, eleven of thirty-eight patients were in remission
at ten weeks. The paediatric use of this drug should be
investigated further; one trial in children aged 12–17 years
is listed on ClinicalTrials.gov as complete, but data is yet to
be published (NCT00055367).
4. Growthand Bone Health
Families and children with CD are often concerned about
the physical and psychosocial impact of impaired growth.
While growth arrest may be a central feature early in the
course of disease, it appears that most children will go
on to achieve an adult height that is within normal limits
[67–69]. Nonetheless, around one-ﬁfth will have impaired
adult height, with late diagnosis and jejunal disease being
predictive factors [69]. When managing growth in CD, the
three general aims are to control disease activity, optimise
nutrition, and minimise the use of corticosteroids (but not
at the expense of poor disease control) [26, 67, 70].
Growth failure mostly appears to be due to disease activ-
ity, with smaller nutritional and iatrogenic components [67].
Growth and pubertal development are inexorably linked
around the time many children develop CD. A growing body
of research describes the complex milieu of cytokines that
modulate growth and development in Crohn’s [71]. There
appears to be a variety of growth impairment phenotypes;
for example, children demonstrate various growth hormone
and insulin-like growth factor-1 (IGF1) deﬁciency states
[72].Thiscausesdiﬃcultyinidentifyingpossibletherapeutic
targets. Translational research implicates interleukin-6 and
TNFα in the suppression of the growth hormone axis, by
inhibiting hepatocyte IGF1 production [73, 74]. In vitro
interleukin-1 and TNFα both inhibit activity at the growth
plate in long bones [75].
By targeting TNFα directly, the anti-TNFα class of med-
ications may improve growth. The REACH study reported
height data only for children with a bone age delay of
at least one year and did not report on a Tanner stage
[40]. z-scores (the number of standard deviations above
or below the mean) were calculated from age- and sex-
matched population values. At baseline, the mean z-score for
height was −1.5. At ﬁfty-four weeks, the mean improvement
in z-score was 0.5 (P<0.001). Despite this impressive
result, given the likely high incidence of pubertal delay
in this group, comparing them with healthy age-matched
controls is of limited value [76]; that is, the improvement in
height may be due to a treatment eﬀect or simply reﬂect a
relative diﬀerence in unmodiﬁed growth velocities between
the treatment group and the population at large.
Three retrospective studies have since provided limited,
yet more compelling, evidence of inﬂiximab’s eﬃcacy in
growth. The ﬁrst describes twenty-seven children (18 male)
with otherwise refractory Crohn’s who received maintenance
inﬂiximab [77]. It found that height and height velocities
are most improved when treatment is initiated before or
during early puberty (Tanner I-III). Treatment has a lesser
eﬀect on growth later in puberty (Tanner IV, V). This
emphasises that timing is critical in gaining control over
disease, at least as far as height is concerned. The second
study described twenty-eight children (17 male) who were
retrospectively assessed over an eighteen-month period,
during which time they all received induction therapy. Some
also received maintenance therapy (n = 12) [78]. In patients
who responded to inﬂiximab (75%), mean improvement
in height velocity was 4.4cm/year, compared to non-
responders whose height velocity remained static. While
manyprogressedintopubertyduringthestudy,childrenwho
remained prepubertal also had improvements in growth.
This suggests that growth is improved independent of any
permissive eﬀect inﬂiximab has on progression into, or
through, puberty. In both studies, there were a proportion
of patients who had sustained growth impairment. This
further emphasises the heterogeneity of growth impairment
phenotypes. Finally, there is some evidence that increasing
inﬂiximab dosing frequency may further improve growth
[79].
Quite apart from the eﬀect of Crohn’s disease on growth,
bone health is impaired, with bone deﬁcits being well docu-
mented in children [80, 81]. Therapy with inﬂiximab results
in dramatic improvements in biomarkers of bone formation
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on the balance of bone formation and resorption. TNFα is
knowntoinhibitosteoblastdiﬀerentiation,inhibitosteoblast
collagen secretion, and induce osteoblast apoptosis [83, 84].
The use of biologics in growth impairment warrants
further investigation. There are no published data regarding
the growth properties of the other anti-TNFα agents or
natalizumab.Giventhatgrowthisuniquetopaediatrics,here
more than in any other areas, randomised controlled trials in
this area are needed.
5.AdverseEffects
5.1. Anti-TNFα Agents. There are a number of toxicities that
may occur in anti-TNFα therapy. These include infusion
reactions, opportunistic infections, dermatological condi-
tions, and malignancy. Mostdata comesfrominﬂiximab use,
and, until more paediatric data are available, these should
be extrapolated to other drugs of the anti-TNFα class. Thus,
close monitoring is required when using any anti-TNFα
agent in children.
Infusion reactions occur commonly with the use of
inﬂiximab and may be severe in some cases. In REACH,
17-18% of children had infusion reactions, while only one
infusion reaction was severe enough to warrant cessation of
inﬂiximab [40]. Retrospective review of children receiving
inﬂiximab infusions at a single centre showed that female
gender and short duration of immunomodulator use were
risk factors for a reaction [85]. It is possible that children
experiencing genuine anaphylactic reactions may be able to
be desensitized through graduated reexposure to an anti-
TNFα agent [86, 87] .T h er a t eo ff u r t h e rs e v e r er e a c t i o n si s
considerable [85, 87]. Reintroduction should be considered
a second-line approach now that alternative biologics are
available. Although patients are often predosed with anti-
histamines and steroids before infusions, there is relatively
little evidence, at least for antihistamines, that these provide
signiﬁcant protection against acute infusion reactions in
children [88].
A large number of children develop antinuclear antibod-
ies (ANAs) after inﬂiximab exposure [40], and to date there
has been at least one reported case of drug-induced lupus in
a child [89]. Data regarding ANA seroconversion in children
exposed to other anti-TNFα agents CH is unavailable.
The development of other autoimmune diseases, such as
demyelinating disease, has not been observed to date in
children with Crohn’s disease although it has occurred in
children given inﬂiximab for other indications.
Serious and/or opportunistic infections are unusual, but
do occur. Adult studies demonstrate similar rates between
placebo and treatment groups, and this is compatible with
the available uncontrolled paediatric data [90]. In REACH,
where most patients were receiving an immunomodulator
and some were receiving corticosteroids, 8% of patients
experienced a serious infection [40]. Two deaths from sepsis
have been reported in children receiving adalimumab in
the context of multiple immunosuppressants and central
venous lines [60]. Concurrent use of anti-TNFα agents
and immunomodulators, particularly in combination with
corticosteroids, is a recognised risk factor for infection
[91]. Cohort studies of children receiving adalimumab and
inﬂiximab have both reported low rates of infection [45,
59]. Reactivation of latent Mycobacterium spp. infections
is of major concern in children with endemic exposure.
One such case is reported in a cohort of children receiving
inﬂiximab [45]. Immunomodulators aﬀect the sensitivity
of immunological tests for M. tuberculosis, so all children
should be screened appropriately before starting therapy
[92]. An added risk with anti-TNF therapy is the reactivation
of chronic viral infection, particularly hepatitis B and herpes
zoster [93].
As with adults [94], there is general agreement with the
importance of screening before embarking on therapy with
ananti-TNFinchildren.Thisshouldincludeacarefulhistory
for risk factors for tuberculosis [95]. Anergy can limit the
value of skin testing with PPD [92], and in vitro speciﬁc
blood tests may be more sensitive and speciﬁc [96], though
there is little information in children. Active infection—
either bacterial, mycobacterial, or viral—poses a particular
risk for exacerbation or dissemination of sepsis in adults [97,
98] with obviously similar risks in children. Immunization
histories are important to obtain, and it may be necessary
to conﬁrm that protective titres are present. If appropriate,
some immunizations may need to be repeated. The severity
of varicella zoster infections in patients on inﬂiximab [97]
arguesstronglyforincludingthisinimmunization.Giventhe
increasingly early use of immunomodiﬁers, immunization
status should be established and appropriately brought up to
date at the ﬁrst diagnosis of inﬂammatory bowel disease in a
child. This anticipatory approach should also include annual
inﬂuenza vaccination, pneumococcal vaccination, human
papillomavirus vaccination to young females, and hepatitis B
to seronegative patients [99]. A history of malignancy is also
recognised to pose a risk factor [95]. There are signiﬁcant
disparities between countries in the practice and extent of
screening before commencing a biological in children [95].
An additional risk for infants is the biological impact of
placenta-fetal passage of anti-TNF therapies. A death after
vaccination from disseminated Bacillus Calmette-Guerin’s
infection has been reported in a 3-month-old otherwise
healthy infant whose mother was being treated with inﬂix-
imab for Crohn’s disease [100].
A paradoxical dermatological eﬀect is inﬂiximab-
induced psoriasis (IIP). IIP appears to occur in children of
both sexes at a rate of 8–10% and to be primarily of the non-
pustular subtypes [55, 101]. They may also occur more on
the facial areas. This contrasts with adults, where lesions are
predominantly of the palmoplantar pustular sub-type [102].
While these lesions are generally mild, their cosmetic impact
may be of great signiﬁcance to children and adolescents.
Malignancy can be considered a rare occurrence with
the use of biologics at this stage. Any discussion of malig-
nancy must be prefaced with mention of the high rate of
malignancy in poorly controlled CD; for example, intestinal
malignancy occurs at a rate of approximately 0.8 cases/1000
person years [103]. For colonic cancer, this is around two to
three times normal, and, for small bowel cancer, there is an
eighteenfold rate increase.6 Gastroenterology Research and Practice
There is some evidence that treatment with anti-TNF
agents may increase the general risk for malignancy [104].
However,ofthemalignanciesin48childrenreportedbyDiak
[104], interpretation was confounded by the potential risk
formalignancyoftheunderlyingconditionandconcomitant
immunosuppression.Concernshavefocussedonlymphoma.
At least one meta-analysis of controlled trials using anti-
TNFα agents in Crohn’s found no increase in cancer risk
overall when compared to placebo [105]. However, a meta-
analysis that also included data from lower-level studies
detected an increased rate of lymphoma in patients receiving
anti-TNFα therapy, when compared to a reference popu-
lation (standardized incidence ratio: 3.23; 95% conﬁdence
interval: 1.5–6.9) [106], but the detection of any increased
riskofmalignancyissobering.Itshouldbenotedthatthereis
no general association between inﬂammatory bowel disease
and lymphoma [107]. One case of lymphoma is reported in
a cohort of children receiving inﬂiximab [45].
Hepatosplenic T-cell lymphoma (HSTCL) is an extreme-
ly rare but mostly fatal malignancy occurring almost exclu-
sively in young males receiving thiopurines [108]. Of thirty-
six reported cases in the CD literature, seventeen were also
receiving anti-TNFα therapy. HSTCL risk can probably be
mostly attributed to thiopurine exposure: in one study of
thiopurine users, the at-risk age bracket was shown to be
at a fourfold increased risk of lymphoma in general [109].
However, it is possible that the risk of HSTCL is additionally
increased with the use of inﬂiximab, and cases of HSTCL
in CD patients receiving anti-TNFα monotherapy may yet
emerge [108]. In the absence of data regarding treatment
eﬀect size of biologic therapy in children, it is extremely
diﬃcult to make evidence-based decisions about the risk
of malignancy in poorly controlled disease compared with
well-controlled disease in patients receiving thiopurines and
biologic drugs. There is a good case to be made for using
thiopurines as an adjunct to reduce the risk of loss of
response to anti-TNFα agent in the ﬁrst year of therapy.
However, the long-term use of both immunomodulator
and anti-TNFα agent should include careful and informed
discussion between the family and physician, particularly
taking account of the implications if the child should lose
response to anti-TNFα therapy. The use of methotrexate as
an alternative agent should be considered, although the risks
of this as an adjunct are not well known.
5.2. Natalizumab. There is only one study regarding the
safety of natalizumab in children [66]. In this study, the
short-term safety proﬁle of the drug was assessed as broadly
similar to that seen in adults. Long-term safety data for
natalizumab in children is currently unavailable.
Progressive multifocal leukoencephalopathy (PML) is
associated with polyomavirus JC reactivation in patients
receiving natalizumab [110] .T h er i s ki sa p p r o x i m a t e l y1
case/1000 patients [111]. It is mostly fatal, and reliable
therapies are not available. After a temporary and voluntary
withdrawal from the market, natalizumab therapy has been
remarketed with strict limitations [112]. Of note in the
context of CD management, there is a requirement for the
cessationofallotherimmunomodulators.Thislikelyrenders
the use of natalizumab impractical for most patients with
CD. Extreme caution should be exercised when using this
unproven therapy in children because of the risk of PML.
6. Access
Regulatory and funding arrangements constrain the use of
biologicals in children. Here we consider the United States
(US), European Union (EU), and Australian jurisdictions.
Inﬂiximab is the only drug with an explicit licence for use
in children around the world. Adalimumab is approved
for use in adults but not approved for use in children. In
the United States, somewhat more permissive licensing has
allowed for the use of certolizumab and natalizumab in adult
CD.ApprovalhaseitherbeenrefusedornotsoughtintheEU
and Australia. Compassionate funding arrangements have
permitted the oﬀ-label use of drugs other than inﬂiximab in
children.
7. Conclusion
There is a need for higher-quality evidence to inform
decision making when using biologics in paediatric Crohn’s.
While it may be argued that children and their families will
notaccepttherisksinvolvedinsuchresearch,onthecontrary
thereisnoreasontoacceptthattreatmentiscurrentlyguided
by little or no rigorous evidence speciﬁc to children [113]. It
is not our intention to present a pessimistic assessment of
biologicals—they have an important and valuable place in
the management of paediatric Crohn’s and their pragmatic
use should continue. Future advancements and new drugs
will come. These may open avenues of therapy for certain
patients, but further gains may be made simply by deepening
our understanding of current therapies.
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